These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38233009)

  • 1. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice.
    Gratacós-Masmitja J; Beltrán Catalán E; Álvarez Vega JL; Urruticoechea-Arana A; Fito C; Maceiras F; Belzunegui Otano JM; Fernández Melón J; Chamizo Carmona E; Abad Hernández MÁ; Ros Vilamajó I; Castro Oreiro S; Pascual Alfonso E; Torre Alonso JC;
    Reumatol Clin (Engl Ed); 2024 Jan; 20(1):24-31. PubMed ID: 38233009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.
    Sfikakis PP; Vassilopoulos D; Katsifis G; Vosvotekas G; Dimitroulas T; Sidiropoulos P; Vounotrypidis P; Bogdanos DP; Georgountzos AΙ; Bounas AG; Georgiou P; Gazi S; Kataxaki E; Liossis SN; Theodorou E; Papagoras C; Theotikos E; Vlachoyiannopoulos P; Voulgari PV; Kekki A; Antonakopoulos N; Boumpas DT
    Rheumatol Int; 2023 May; 43(5):889-902. PubMed ID: 36856816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study.
    de Vlam K; Toukap AN; Kaiser MJ; Vanhoof J; Remans P; Van den Berghe M; Di Romana S; Van den Bosch F; Lories R
    Adv Ther; 2022 Feb; 39(2):1055-1067. PubMed ID: 34977986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
    Wu JJ; Pelletier C; Ung B; Tian M
    Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
    [No Abstract]   [Full Text] [Related]  

  • 6. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
    Wells AF; Edwards CJ; Kivitz AJ; Bird P; Guerette B; Delev N; Paris M; Teng L; Aelion JA
    Rheumatology (Oxford); 2022 Mar; 61(3):1035-1043. PubMed ID: 34100922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
    Venerito V; Natuzzi D; Bizzoca R; Lacarpia N; Cacciapaglia F; Lopalco G; Iannone F
    Clin Exp Immunol; 2020 Aug; 201(2):200-204. PubMed ID: 32383167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study.
    Chandran V; Bessette L; Thorne C; Sheriff M; Rahman P; Gladman DD; Anwar S; Jelley J; Gaudreau AJ; Chohan M; Sampalis JS
    Rheumatol Ther; 2024 Apr; 11(2):443-455. PubMed ID: 38416391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.
    Ohtsuki M; Okubo Y; Saeki H; Igarashi A; Imafuku S; Abe M; Chaudhari S; Yaguchi M; Emoto A; Morita A
    J Dermatol; 2024 Jul; 51(7):950-963. PubMed ID: 38775204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice.
    Werner SG; Baraliakos X; Reckert S; Bohl-Bühler M; Laliberté MC; Girard T; Jeromin K; Baschuk N; Fritz B; Bessette L; Hueber AJ
    Rheumatol Ther; 2023 Dec; 10(6):1503-1518. PubMed ID: 37695506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
    Favalli EG; Conti F; Selmi C; Iannone F; Bucci R; D'Onofrio F; Carlino G; Santo L; Semeraro A; Zuccaro C; D'Angelo S; Atzeni F; Marino F; Monti S; Guidelli GM; Spinelli FR; Biggioggero M; Caporali R
    Clin Exp Rheumatol; 2020; 38(1):19-26. PubMed ID: 31074721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Young P; Fallon L; Mundayat R; Dina O; Blachley T; Middaugh N; Ogdie A
    Rheumatol Ther; 2024 Apr; 11(2):313-329. PubMed ID: 38252211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
    Ghislain PD; Lambert J; Lam Hoai XL; Hillary T; Roquet-Gravy PP; de la Brassinne M; Segaert S
    Adv Ther; 2022 Feb; 39(2):1068-1080. PubMed ID: 34977985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.